0001209191-22-058493.txt : 20221122 0001209191-22-058493.hdr.sgml : 20221122 20221122184606 ACCESSION NUMBER: 0001209191-22-058493 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221121 FILED AS OF DATE: 20221122 DATE AS OF CHANGE: 20221122 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: York Charles N II CENTRAL INDEX KEY: 0001655962 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40431 FILM NUMBER: 221411865 MAIL ADDRESS: STREET 1: 901 S. MOPAC EXPRESSWAY STREET 2: BARTON OAKS PLAZA ONE, SUITE 250 CITY: AUSTIN STATE: TX ZIP: 78746 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Day One Biopharmaceuticals, Inc. CENTRAL INDEX KEY: 0001845337 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 832415215 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2000 SIERRA POINT PARKWAY, SUITE 501 CITY: BRISBANE STATE: CA ZIP: 94080-1930 BUSINESS PHONE: 650 484-0899 MAIL ADDRESS: STREET 1: 2000 SIERRA POINT PARKWAY, SUITE 501 CITY: BRISBANE STATE: CA ZIP: 94080-1930 FORMER COMPANY: FORMER CONFORMED NAME: Day One Biopharmaceuticals Holding Co LLC DATE OF NAME CHANGE: 20210209 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-11-21 0 0001845337 Day One Biopharmaceuticals, Inc. DAWN 0001655962 York Charles N II 2000 SIERRA POINT PARKWAY, SUITE 501 BRISBANE CA 94080 0 1 0 0 COO, CFO and Secretary Common Stock 2022-11-21 4 S 0 9700 20.7374 D 286797 D Common Stock 2022-11-21 4 S 0 300 21.39 D 286497 D The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.33 to $21.27 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.35 to $21.43 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Charles N. York II 2022-11-22